Peptide Romania
metabolic

Tirzepatide

GLP-1 / GIP

Dual incretin agonist with weight and glycemic outcomes in late-stage trials.

Dovezi
Strong
T½
~120 h
Categorie
metabolic
Status
FDA approved

Evaluarea dovezilor

Baza de dovezi

Strong100%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Dual incretin agonist with weight and glycemic outcomes in late-stage trials.

T½~120 h
StatusFDA approved
Categoriemetabolic
DoveziStrong

Întrebări frecvente

Ce trebuie să știi

Dual incretin agonist with weight and glycemic outcomes in late-stage trials.
Tirzepatide has Strong evidence. Multiple peer-reviewed human trials with consistent, replicated outcomes confirm its biological activity across independent research groups. This is the highest evidence tier.
The half-life of Tirzepatide is ~120 h. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
Tirzepatide is currently classified as: FDA approved. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Dual incretin agonist with weight and glycemic outcomes in late-stage trials.
Înapoi la peptide